- Home
- NCPL vs HEPA Comparison
NCPL vs HEPA Comparison
Compare NCPL & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- HEPA
- Stock Information
- Founded
- NCPL 1984
- HEPA 2013
- Country
- NCPL United States
- HEPA United States
- Employees
- NCPL N/A
- HEPA N/A
- Industry
- NCPL Investment Managers
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- HEPA Health Care
- Exchange
- NCPL Nasdaq
- HEPA Nasdaq
- Market Cap
- NCPL 3.9M
- HEPA 4.1M
- IPO Year
- NCPL N/A
- HEPA N/A
- Fundamental
- Price
- NCPL $2.07
- HEPA $0.16
- Analyst Decision
- NCPL
- HEPA
- Analyst Count
- NCPL 0
- HEPA 0
- Target Price
- NCPL N/A
- HEPA N/A
- AVG Volume (30 Days)
- NCPL 116.3K
- HEPA 51.5M
- Earning Date
- NCPL 03-17-2025
- HEPA 11-14-2024
- Dividend Yield
- NCPL N/A
- HEPA N/A
- EPS Growth
- NCPL N/A
- HEPA N/A
- EPS
- NCPL N/A
- HEPA N/A
- Revenue
- NCPL $1,702,723.00
- HEPA N/A
- Revenue This Year
- NCPL N/A
- HEPA N/A
- Revenue Next Year
- NCPL $101.16
- HEPA N/A
- P/E Ratio
- NCPL N/A
- HEPA N/A
- Revenue Growth
- NCPL N/A
- HEPA N/A
- 52 Week Low
- NCPL $1.41
- HEPA $0.12
- 52 Week High
- NCPL $22.82
- HEPA $3.49
- Technical
- Relative Strength Index (RSI)
- NCPL 57.35
- HEPA 31.96
- Support Level
- NCPL $1.99
- HEPA $0.15
- Resistance Level
- NCPL $2.12
- HEPA $0.28
- Average True Range (ATR)
- NCPL 0.11
- HEPA 0.06
- MACD
- NCPL 0.02
- HEPA -0.01
- Stochastic Oscillator
- NCPL 89.19
- HEPA 10.20
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.